What is William Blair’s Forecast for EW FY2024 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Research analysts at William Blair issued their FY2024 EPS estimates for Edwards Lifesciences in a report issued on Tuesday, October 29th. William Blair analyst M. Kaczor forecasts that the medical research company will post earnings of $2.58 per share for the year. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.61 per share. William Blair also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.56 EPS.

Other analysts also recently issued reports about the stock. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Piper Sandler dropped their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday. Finally, Robert W. Baird dropped their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Sixteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Trading Down 1.1 %

Shares of EW opened at $68.63 on Thursday. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a market cap of $41.36 billion, a price-to-earnings ratio of 29.58, a PEG ratio of 3.00 and a beta of 1.13. The firm has a 50 day moving average price of $68.07 and a 200-day moving average price of $77.92. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the company posted $0.59 EPS. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EW. Price T Rowe Associates Inc. MD raised its holdings in Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares during the last quarter. CCLA Investment Management raised its stake in shares of Edwards Lifesciences by 100,739.7% in the first quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock worth $134,092,000 after purchasing an additional 1,405,319 shares during the last quarter. Swedbank AB bought a new position in shares of Edwards Lifesciences during the first quarter valued at $124,511,000. Sei Investments Co. boosted its position in shares of Edwards Lifesciences by 162.7% during the first quarter. Sei Investments Co. now owns 1,465,719 shares of the medical research company’s stock valued at $140,064,000 after buying an additional 907,688 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after buying an additional 809,605 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,250 shares of company stock valued at $1,099,238. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.